Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active RA. A Multicenter Post-Marketing Observational Study in Routine Clinical Use.

Trial Profile

Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active RA. A Multicenter Post-Marketing Observational Study in Routine Clinical Use.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2012

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms FALLA
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 30 Dec 2011 Actual patient number changed from 84 to 82 as reported by ClinicalTrials.gov.
    • 21 Mar 2011 Actual initiation date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
    • 21 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top